Connecting the pharmacy dots
Drug Store News speaks with Lori Ann Hamilton, director of healthy initiatives at Food City.
Drug Store News: In your view, what is the important role that supermarket pharmacy plays in health care?
Lori Ann Hamilton: One of the first things that we’ve done is look at the fact that inactivity is a major health risk for so many medical conditions, so we did a “Food City Fitness 250” on the Web, and all of our associates could access it. It was a fun way to get them up and moving. For every 30 minutes they exercised, they got a lap.… We saw that it motivated people in our stores to get up and start moving. So we then started in October with a football theme.… We will start Jan. 1 with a Food City Fitness 500 playing upon the Nascar 500.
I am a registered nurse, so I look at it as the pharmacists are a key component to the whole team that helps an individual with their care and health and wellness.… The pharmacist is accessible, knowledgeable and also well-rounded to help [the consumer], and has more time [than a physician]. They are a trusted part of the healthcare team.
Walgreens offering free review sessions to Medicare Part D beneficiaries
DEERFIELD, Ill. Walgreens now is offering free review sessions to Medicare Part D beneficiaries at all of its more than 7,100 pharmacies throughout the country.
Following the open enrollment period for Medicare Part D insurance plans, Walgreens is assisting those beneficiaries who’ve made changes to their prescription drug coverage. Review sessions with Walgreens pharmacists are available daily by appointment through Jan. 31, and are designed to help patients maximize their plan benefits.
Review sessions include:
- A review of beneficiary’s current medications, tiers within their selected plan, co-pays and cost-savings opportunities
- Discussion of available health and wellness services including pneumonia and shingles vaccinations and 90-day prescription benefits
- Checks for potential drug interactions
Watson files FDA application for generic LoSeasonique
MORRISTOWN, N.J. Watson Labs, a subsidiary of specialty pharmaceutical company Watson Pharmaceuticals, has filed an abbreviated new drug application to the Food and Drug Administration for an oral contraceptive.
Watson is seeking approval to market its levonorgestrel and ethinyl estradiol (0.10-mg/0.02-mg) oral contraceptive product prior to the expiration of U.S. Patent No. 7,615,545, which is owned by Duramed Pharmaceuticals, a subsidiary of Teva. Watson’s levonorgestrel and ethinyl estradiol product is a generic version of Teva’s LoSeasonique, which is indicated for the prevention of pregnancy.
On Nov. 23, 2009, pursuant to the Hatch-Waxman Act, Watson notified Duramed that its ANDA requesting approval from the FDA for a generic version of LoSeasonique contained a paragraph IV certification asserting that the LoSeasonique patent is invalid, unenforceable and/or not infringed. Teva Women’s Health filed suit against Watson on Jan. 6, 2010 in the U.S. District Court for the District of New Jersey seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent No. 7,615,545. Based on available information, Watson believes it may be entitled to 180 days of generic market exclusivity or shared exclusivity should its product receive approval.